Sanofi(GCVRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GCVRZ Sanofi

停牌 03-03 16:00:00 EST

0.8711

+0.0000

0.00%

最高0.8711	最低0.8711	成交量0.00
今开0.8711	昨收0.8711	日振幅0.00%
总市值10.92亿	流通市值9.71亿	总股本12.54亿
成交额0.00	换手率0.00%	流通股本11.15亿
市净率0.02	ROE4.97%	每股收益2.52
52周最高0.8820	52周最低0.3400	市盈率0.35
股息3.66	股息收益率4.20	ROA4.03%

北京优虎网络科技有限公司

{"stockData":{"symbol":"GCVRZ","market":"US","secType":"STK","nameCN":"Sanofi","latestPrice":0.8711,"timestamp":1583269200000,"preClose":0.8711,"halted":3,"volume":0,"delay":0,"floatShares":1114622547,"shares":1254041488,"eps":2.519335,"marketStatus":"停牌","change":0,"latestTime":"03-03 16:00:00 EST","open":0.8711,"high":0.8711,"low":0.8711,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.519335,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752739200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.8711,"dividendRate":4.027632,"volumeRatio":0},"requestUrl":"/m/hq/s/GCVRZ","defaultTab":"news","newsList":[{"id":"2551193109","title":"美国OTC市场Sanofi盘中异动 股价大跌5.08%报94.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551193109","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551193109?lang=zh_cn&edition=full","pubTime":"2025-07-15 22:46","pubTimestamp":1752590761,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日22时46分，美国OTC市场Sanofi股票出现波动，股价急速跳水5.08%。截至发稿，该股报94.35美元/股，成交量486股，换手率0.00%，振幅0.00%。美国OTC市场Sanofi股票所在的制药行业中，整体跌幅为1.42%。美国OTC市场Sanofi公司简介：赛诺菲专注于疫苗、免疫学、肿瘤学、心血管疾病、糖尿病和非处方治疗药物的开发和销售。超过40%的总收入来自美国，25%来自欧洲。新兴市场占据了剩余收入的大部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715224601a44cac37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715224601a44cac37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GCVRZ","SNYNF","BK4007"],"gpt_icon":0},{"id":"2545100384","title":"赛诺菲将于第三季度开始全球运送Beyfortus RSV预防治疗药物Sanofi to Begin Global Shipments of Beyfortus RSV Prevention Treatment in Third Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2545100384","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545100384?lang=zh_cn&edition=full","pubTime":"2025-06-21 14:06","pubTimestamp":1750485960,"startTime":"0","endTime":"0","summary":"The decision comes as part of Sanofi’s strategy to ensure timely availability of Beyfortus, particularly during a period when demand for RSV prevention typically increases. By initiating shipments in Q3, the company aims to support healthcare systems worldwide in preparing for the seasonal rise in RSV cases.该决定是赛诺菲确保 Beyfortus 及时供应战略的一部分，尤其是在对 RSV 预防需求通常增加的时期。通过在第三季度开始发货，该公司旨在支持全球医疗系统为 RSV 病例的季节性增长做好准备。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621140922952592c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621140922952592c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFXG1179.USD","SNY","BK4588","BK4007","BK4585","SNYNF","GCVRZ"],"gpt_icon":0},{"id":"2539221846","title":"赛诺菲和再生元公司报告了针对IL-33通路的COPD药物的混合三期试验结果Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2539221846","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539221846?lang=zh_cn&edition=full","pubTime":"2025-05-30 19:09","pubTimestamp":1748603340,"startTime":"0","endTime":"0","summary":"Following the announcement, both companies experienced a decline in their stock prices..公告发布后，两家公司的股价均出现下跌。The studies assessed itepekimab’s efficacy in reducing exacerbations among COPD patients who were former smokers. While the drug showed potential in lowering flare-ups compared to standard treatments, it did not achieve statistically significant improvements across all primary endpoints. The trials aimed to explore whether targeting interleukin-33 , an inflammatory pathway linked to COPD progression, could offer new therapeutic benefits.这些研究评估了伊替普单抗在减少曾吸烟的慢性阻塞性肺病患者急性加重方面的疗效。试验旨在探索针对白细胞介素-33这一与COPD进展相关的炎症通路，是否能提供新的治疗益处。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530191327950828f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"b3a9ed5a6b4b1af59b0d713f5210f4fb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530191327950828f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0114720955.EUR","LU0882574055.USD","LU0289739699.SGD","BK4588","LU2362540622.SGD","BK4007","LU2106854487.HKD","LU2362541273.HKD","LU2468319806.SGD","LU0823434583.USD","LU1974910355.USD","LU1917777945.USD","LU0823434740.USD","LU0053666078.USD","LU2023250504.SGD","SNY","LU0823416689.USD","LU0058720904.USD","LU0109394709.USD","LU2089984988.USD","BK4585","BK4139","LU0889565916.HKD","LU0320765992.SGD","REGN","LU2237438978.USD","LU2362541513.USD","GCVRZ","SNYNF"],"gpt_icon":0},{"id":"2537092982","title":"Viz.ai与赛诺菲和再生元合作，利用人工智能技术改善COPD护理Viz.ai Partners with Sanofi and Regeneron to Improve COPD Care with AI Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2537092982","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537092982?lang=zh_cn&edition=full","pubTime":"2025-05-21 19:14","pubTimestamp":1747826040,"startTime":"0","endTime":"0","summary":"Viz.ai has announced a multi-year collaboration with global healthcare company Sanofi and biotechnology firm Regeneron to support the management of chronic obstructive pulmonary disease  using artificial intelligence .Viz.ai 宣布与全球医疗保健公司赛诺菲和生物技术公司再生元达成多年合作，利用人工智能  支持慢性阻塞性肺疾病  的管理。Through this partnership, Viz.ai, Sanofi, and Regeneron aim to address gaps in COPD care by advancing the use of AI to support earlier intervention and improve outcomes for patients living with this serious respiratory disease.通过这一合作，Viz.ai、赛诺菲和再生元旨在通过推进人工智能的使用来弥补COPD护理中的不足，支持更早的干预，并改善患有这种严重呼吸系统疾病患者的结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505211915209760b85e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505211915209760b85e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2089984988.USD","LU0823416689.USD","REGN","LU0053666078.USD","LU0109394709.USD","LU2362541513.USD","LU2468319806.SGD","LU0889565916.HKD","LU0823434583.USD","LU0823434740.USD","LU2362540622.SGD","LU2106854487.HKD","SNY","LU2023250504.SGD","LU0320765992.SGD","BK4007","LU0114720955.EUR","BK4585","LU1974910355.USD","LU2237438978.USD","GCVRZ","LU0058720904.USD","LU0289739699.SGD","SNYNF","LU1917777945.USD","BK4588","LU0882574055.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2535692001","title":"SP0273 & SP0237——Sanofi流感疫苗管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2535692001","media":"生物制品圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535692001?lang=zh_cn&edition=full","pubTime":"2025-05-14 23:02","pubTimestamp":1747234975,"startTime":"0","endTime":"0","summary":"2024年7月25日，Sanofi发布的第二季度财报中，流感疫苗作为公司的优势品种，二季度销售额达到了1.15亿欧元。在2023年6月举办的Sanofi投资者活动上，公司公布了SP0273疫苗的最新试验结果。图2SP0273的临床试验结果此外，在同一活动上，Sanofi还透露了一项令人振奋的研发进展，公司正借助机器学习的力量，致力于新一代流感mRNA疫苗的研发。不过，这一变动并未减缓Sanofi在流感mRNA疫苗研发领域的步伐。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515025403a47e821c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515025403a47e821c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GCVRZ","IE00BFXG1179.USD","BK4585","BK4007","SNYNF","SNY","BK4588"],"gpt_icon":0},{"id":"2529464230","title":"Sanofi：2025年Q1财报实现营收104.06亿美元，前值为113.64亿美元；每股收益为0.94美元，前值为0.97美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529464230","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529464230?lang=zh_cn&edition=full","pubTime":"2025-04-24 13:44","pubTimestamp":1745473464,"startTime":"0","endTime":"0","summary":"Sanofi(SNY.US)：2025年Q1财报实现营收104.06亿美元，前值为113.64亿美元；每股收益为0.94美元，前值为0.97美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504241348229743192f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504241348229743192f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GCVRZ","SNYNF","SNY"],"gpt_icon":0},{"id":"2507107986","title":"Sanofi(SNY.US)：2024年Q4财报实现营收112.75亿美元，前值为117.53亿美元，预期值为105.7亿美元；每股收益为0.70美元，前值为0.89美元，预期值为0.74美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507107986","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507107986?lang=zh_cn&edition=full","pubTime":"2025-01-30 17:13","pubTimestamp":1738228394,"startTime":"0","endTime":"0","summary":"Sanofi(SNY.US)：2024年Q4财报实现营收112.75亿美元，前值为117.53亿美元，预期值为105.7亿美元；每股收益为0.70美元，前值为0.89美元，预期值为0.74美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30171347906752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SNYNF","GCVRZ","SNY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sanofi.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0029},{"period":"1month","weight":0.0421},{"period":"3month","weight":0.1835},{"period":"6month","weight":0.0516},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.0615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sanofi-Aventis is a global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Co.'s business includes two main activities: pharmaceuticals and human vaccines (Vaccines).","exchange":"NASDAQ","name":"Sanofi","nameEN":"Sanofi SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sanofi(GCVRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sanofi(GCVRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sanofi,GCVRZ,Sanofi股票,Sanofi股票老虎,Sanofi股票老虎国际,Sanofi行情,Sanofi股票行情,Sanofi股价,Sanofi股市,Sanofi股票价格,Sanofi股票交易,Sanofi股票购买,Sanofi股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sanofi(GCVRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sanofi(GCVRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}